Condition 1: Coronary artery bypass graft. Condition 2: Diabet melitus. Condition 3: Atrial fibrilation. Condition 4: Deliriom. Condition 5: Acute myocardial ischemia and infarction. Mechanical complication of coronary artery bypass and valve grafts Insulin-dependent diabetes mellitus-Non-insulin-dependent diabetes mellitus Atrial fibrillation and flutter Delirium, not induced by alcohol and other psychoactive substances Acute myocardial infarction
Conditions
Interventions
Intervention 1: Patients in this study werw generally used 10 to 20 mg atorvastatin daily. Patients in this group, recived Atorvastatin 80 mg daily for 3 days before surgery and received postoperativ
Treatment - Drugs
Patients in this study werw generally used 10 to 20 mg atorvastatin daily. Patients in this group, recived Atorvastatin 80 mg daily for 3 days before surgery and received postoperative low dose of 20
The control group received 20 mg atorvastatin daily and continues in ICU
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients admitted in Nemazee hospital who underwent CABG on CPB; after learning of the investigation and completed an informed consent, were randomized to receive atorvastatin are divided into two groups. Exclusion criteria: unstable angina; myocardial infarction; evidence of recent MI (within 6 months); history of previous cardiac surgery; emergency surgery; congenital heart disease; a history of cardiac arrhythmias (Atrial Fibrilation) preoperatively received antiarrhythmic drugs (except Beta blocker); having Pacemaker; Left Ventricle Edjection Fraction less than 30%; uncontrolled hypertension; persistant atrial or ventricular arrhythmia; pregnant women; a history of diabet under treatment; elevated liver enzymes; renal failure with creatinine greater than 2mg/dl; inflammation or immune activation; muscle disease and alergy to statins.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CK-MB. Timepoint: Befor induction, 24 and 48 h after surgery. Method of measurement: Labratory kit.;CRP. Timepoint: Befor induction, 24 and 48 h after surgery. Method of measurement: Laberatory kit.;Blood suger. Timepoint: Before induction, in pump, after off pump, every 6h upto48 h, then daily. Method of measurement: Glucometr.;Atrial fibrilation. Timepoint: During operation, in course of ICU admission. Method of measurement: Continioues ECG monitoring.;MACE(magor adverse cardiac events). Timepoint: In ICU and up to 1 month after surgery. Method of measurement: Echocardiography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Ceratinin. Timepoint: Before surgery, daily up to 3 days. Method of measurement: Laberatory kit.;Hematocrit. Timepoint: Before surgery,in pump,off-pump,days of 1&2&3. Method of measurement: Laberatoty kit.;Liver function tests. Timepoint: Befor surgery,second day after operation. Method of measurement: Lab kit.;Delirium. Timepoint: In course of ICU admission. Method of measurement: Richmond scale daily. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMisagh Bastani
Shiraz University of Medical Sciences
Outcome results
None listed